Raemaekers et al (SEE ARTICLE) measured
brain activity in schizophrenic patients and healthy control subjects during
3 oculomotor tasks using event-related functional magnetic resonance imaging.
Patients engaged the frontal brain regions normally during saccadic inhibition.
In contrast with controls, however, they did not activate the striatum, suggesting
a frontostriatal abnormality rather than a selective frontal malfunction during
inhibition.
Left temporal auditory P300 amplitude reduction is associated with reduced
gray matter volume of the left posterior superior temporal gyms (LPSTG) in
chronic schizophrenia. To determine whether this association was present at
first episode and specific to schizophrenia, McCarley et
al (SEE ARTICLE) evaluated healthy normal controls and patients
with schizophrenia and affective (mainly manic) psychosis at first hospitalization.
Specific to schizophrenia were findings of P300 left temporal amplitude reduction,
LPSTG matter volume reduction, and LPSTGleft temporal P300 correlation.
These data suggest that interrelated functional and structural temporal lobe
abnormalities are specific and critical features of both early and chronic
schizophrenia.
McCreadie et al (SEE ARTICLE) have
previously found in southern India that spontaneous dyskinesia is common in
chronically ill, never-treated schizophrenic patients. They now report brain
structure findings from magnetic resonance imaging. The left lenticular nucleus
is larger in dyskinetic patients, and the lateral ventriclehemisphere
ratio is larger in nondyskinetic patients when compared with controls. In
controls but not patients, increasing age was associated with decreased basal
ganglia volume. The results suggest a subgroup of schizophrenia: dyskinetic
patients with striatal pathology.
Hyperglycemia and type 2 diabetes mellitus are reported to be more common
in schizophrenic patients than in the general population. Glucoregulatory
abnormalities have also been associated with antipsychotic treatment. Newcomer et al (SEE ARTICLE) report that during
fasting oral glucose tolerance tests, nondiabetic patients taking olanzapine
and clozapine had higher plasma glucose levels than age- and adiposity-matched
patients taking typical antipsychotics. Patients taking olanzapine, clozapine,
and risperidone had higher plasma glucose levels compared with matched controls.
Daskalakis et al (SEE ARTICLE) reported
that cortical inhibition is impaired in unmedicated patients with schizophrenia.
In medicated patients cortical inhibition is increased compared with their
unmedicated counterparts. Their results suggest that schizophrenia is associated
with deficits in cortical inhibition that may be normalized with antipsychotic
medications.
Fenton et al (SEE ARTICLE) evaluated
the cost-effectiveness of acute care in a crisis residential setting for patients
with serious mental illness willing to accept voluntary treatment. Compared
with usual treatment in a hospital psychiatric ward, the crisis residential
model reduced episode and 6-month treatment costs while delivering comparable
symptom reduction and days of community functioning. Access to acute care
might be extended using a mix of hospital, crisis residential, and community
support services.
In a community sample of adolescents and young adults, Lieb et al (SEE ARTICLE) found that offspring of depressed
parents have elevated rates of depressive disorders and other mental disorders,
such as specific anxiety and substance use disorders. Offspring with 2 affected
parents had an earlier onset of depression than those without affected parents.
Offspring of affected parents also reported a more malignant course of depression,
suggesting that parental depression seems to influence the natural course
of depression in the early stages of manifestation.
Difficulty diagnosing major depressive disorder in alcohol- and drug-abusing
patients has led to inconsistencies with the relationship of depression to
substance outcome. Hasin et al (SEE ARTICLE) present evidence of differential effects of major depression occurring under
different temporal relationships to substance dependence. Research on the
reasons for differences in the effects (for example, effects of different
levels or types of disability) may yield clinically useful information.
Phillips et al (SEE ARTICLE) studied
response to fluoxetine in the first placebo-controlled study of body dysmorphic
disorder (BDD). Fluoxetine was generally well tolerated and significantly
more efficacious than placebo for BDD, beginning at week 8 and continuing
at weeks 10 and 12. Symptoms were as likely to improve in patients with delusional
BDD as in those who were nondelusional. This study indicates that fluoxetine
is safe and effective for both delusional and nondelusional BDD.